A Phase II, Multi-Center Study of a New Non-Cytotoxic A3 Adenosine Receptor Agonist CF101, Dose-Finding (randomized Blinded) in Patients (pts)with Refractory Metastatic Colorectal Cancer
JOURNAL OF CLINICAL ONCOLOGY（2004）
Key words
Adenosine Receptors,Alpha Particle Therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined